Core Insights - AptarGroup, Inc. is recognized as one of the most oversold healthcare stocks in 2025 [1] - The company showcased its growth strategy and positive long-term outlook during its Investor Day on September 9, 2025, highlighting strong momentum in the Pharma segment [2] Financial Performance - In Q2 2025, AptarGroup reported a 6% increase in revenue year-over-year, with net income rising 24% to $112 million and adjusted EBITDA increasing by 13% [3] - Earnings per share grew by 25%, driven by operational efficiencies and strong demand in the Pharma and Closures segments [3] Shareholder Returns - The company announced a nearly 7% increase in its quarterly dividend to $0.48 per share, marking 32 consecutive years of dividend growth [4] - AptarGroup returned $100 million to shareholders through dividends and share repurchases in Q2, totaling $210 million for the first half of the year, reflecting a shareholder-friendly capital allocation strategy [4]